Key targets include isocitrate dehydrogenase-1 (IDH1), fibroblast growth factor receptor-2 (FGFR2), human epidermal growth factor receptor-2 (HER2/ERBB2), proto-oncogene B-Raf (BRAF), high tumour mutational burden (TMB-H), high microsatellite instability or mismatch repair deficiency (MSI-H/dMMR), neurotrophic tyrosine receptor kinase (NTRK) fusions, and rearranged during transfection (RET) fusions. The gene discussed is BRAF; the disease is neoplasm.